<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617495</article-id><article-id pub-id-type="pmc">5873786</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0087</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Early Clinical Results of Perceval Sutureless Aortic Valve in 139
Patients: Freeman Experience</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mujtaba</surname><given-names>Syed Saleem</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Ledingham</surname><given-names>Simon</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Asif Raza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Clark</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Pillay</surname><given-names>Thasee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Schueler</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><aff id="aff1">
<label>1</label> Department of Cardiothoracic Surgery, Freeman Hospital, Freeman
Road, United Kingdom of Great Britain and Northern Ireland. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Stephan Schueler, Department of
Cardiothoracic Surgery, Freeman Hospital, Freeman Road Newcastle upon Tyne, NE3
1YS, United Kingdom. E-mail: <email>stephan.schueler@nuth.nhs.uk</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><history><date date-type="received"><day>03</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>28</day><month>7</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The aim of this retrospective study is to evaluate the safety and performance
of the Perceval sutureless valve in patients undergoing aortic valve
replacement. We report the 30-day clinical outcomes of 139 patients.</p></sec><sec><title>Methods</title><p>From January 2014 to December 2016, 139 patients underwent sutureless aortic
valve replacement. Their operation notes, National Adult Cardiac Surgery
Database and perioperative transoesophageal echocardiography findings were
studied retrospectively.</p></sec><sec><title>Results</title><p>Ninety-two patients underwent isolated aortic valve replacement (group A)
with Perceval valve and 47 patients had combined procedures of aortic valve
replacement and coronary artery bypass grafting (group B). The patients
received a size S (n=23), M (n=39), L (n=42) or XL (n=35) prosthesis.
Perceval valve was successfully implanted in 135 (97.1%) patients. Mean
cross-clamping time and bypass time were 40 and 63 minutes for isolated
cases, while 68 and 107 minutes for combined cases. Three (2.1%) patients
died within 30 days. Four patients suffered stroke and 5 patients went into
acute renal failure. Median intensive care unit and hospital stay was 2 and
8.5, respectively. Four valves were explanted due to significant
paravalvular leak after surgery. Five patients had permanent pacemaker as a
result of complete heart block and mean postoperative drainage was 295 mL
for isolated case and 457 mL for combined cases. The mean gradient across
Perceval valve was 12.5 mmHg while its effective orifice area was 1.5
cm<sup>2</sup>.</p></sec><sec><title>Conclusion</title><p>Early postoperative results showed that Perceval valve is safe. Further
follow up is needed to evaluate the long-term outcome with this
bioprosthesis.</p></sec></abstract><kwd-group><kwd>Aortic valve stenosis</kwd><kwd>Aortic Valve/Surgery</kwd><kwd>Bioprosthesis</kwd><kwd>Heart Valve Prosthesis</kwd><kwd>Heart Valve Prosthesis Implantation/Methods</kwd><kwd>Minimally Invasive Surgical Procedures</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Aortic valve
replacement</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EuroSCORE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= European System for
Cardiac Operative Risk Evaluation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FEV1</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Forced expiratory volume
in 1 second</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NACSA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= National Adult Cardiac
Surgery Audit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NICOR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= National Institute for
Cardiovascular Outcomes Research</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PVL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Paravalvular leak</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SCTS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Society for
Cardiothoracic Surgeons</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">STS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Society of Thoracic
Surgeons</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transfemoral aortic
valve implantation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TOE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transesophageal
echocardiography</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Severe aortic valve stenosis is a common cardiac disease among the elderly. Due to
the increasing age of the patient population in the Western world, there has been an
increase in the prevalence of patients with valvular heart disease eligible for
aortic valve replacement (AVR)<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. AVR is the treatment of choice for aortic valve
stenosis when it is severe aortic stenosis (&#x02264; 1 cm<sup>2</sup>/m<sup>2</sup>)
and symptomatic, or asymptomatic with left ventricular dysfunction, or combined with
other cardiac surgery procedure<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Given the increasing number of comorbidities and
increasing patient age, a tendency has emerged to use biological valve implants,
avoiding the need for long-term anticoagulation therapy.</p><p>Although transapical or transfemoral aortic valve implantations (TAVIs) have been
introduced for high-risk patients ineligible for conventional AVR using
cardiopulmonary bypass (CPB), it has its own limitations, <italic>e.g</italic>.,
significantly increased costs, inability to remove the calcified aortic valve, and
the high incidence of paravalvular leak (PVL), pacemaker implantation and
neurological events<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>In last few years sutureless aortic valve bioprostheses have been developed to
facilitate surgical AVR, reduce aortic cross-clamping and CPB time and curtail risk
of mortality and morbidity. Sutureless aortic bioprosthesis implantation is a
feasible alternative for high-risk patients with aortic valve
disease<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>.
The Perceval valve (Sorin Group, Saluggia, Italy) is a bioprosthetic heart valve
made of bovine pericardium that allows a fast implantation through a sutureless
technique. The current study reports our single-centre experiences regarding the
early outcomes of Perceval valve implantation.</p></sec><sec sec-type="methods"><title>METHODS</title><p>The Perceval valve is a surgical bioprosthetic heart valve composed of
glutaraldehyde-fixed bovine pericardium treated with homocysteic acid in order to
remove the free aldehyde residues and prevent the calcification process. It is fixed
in a metal cage made up of an alloy of nickel and titanium, known as nitinol.
Currently, four sizes of the Perceval S aortic valve prosthesis are available: small
- S (19-21 mm); medium - M (22-23 mm), large - L (24-25 mm) and extra-large XL (27
mm). Hence, Perceval S can be used for annulus sizes ranging from 19 to 27 mm.</p><p>We performed a retrospective analysis of a consecutive series of patients (n = 139)
who underwent AVR with Perceval valve between January 2014 and December 2016. They
were either isolated AVR (group A, n = 92) or combined with coronary artery bypass
grafting (CABG, group B, n = 47). Inclusion criteria were severe aortic valve
stenosis with indication of valve replacement, patients who agreed to participate in
the clinical evaluation, patients wishing to have a tissue valve, no
contraindication for Perceval valve, and signed informed consent. These patients
were operated by six different surgeons. During the same period, 312 patients had
AVR with conventional Perimount Magna biological valve by four different
surgeons.</p><p>Patients with ascending aortic aneurysm or dissection, emergency intervention, acute
endocarditis, congenital bicuspid aortic valve (Seivers type 0) or aortic annulus
greater than 27 mm or less than 21 mm were excluded. The ratio between the diameter
of the sinotubular junction and aortic annulus should not exceed 1.3 mm. Patients
with known nickel hypersensitivity were also avoided.</p><p>The operative risk of these patients was estimated according to the logistic European
System for Cardiac Operative Risk Evaluation (logistic EuroSCORE). In this study, we
have used logistic EuroSCORE as we submit patient's risk assessment as logistic
EuroSCORE to National Adult Cardiac Surgery Audit (NACSA) database and it is easier
to retrieve in this form. The data used in this analysis were extracted from NACSA.
The audit is managed by National Institute for Cardiovascular Outcomes Research
(NICOR), with clinical direction and strategy provided by the Society for
Cardiothoracic Surgeons (SCTS) and the Project Board.</p><sec><title>Surgical Technique</title><p>After a full median sternotomy, standard CPB was established by cannulation of
the ascending aorta and the right atrium. The heart is vented through the right
superior pulmonary vein. Antegrade cardioplegia is the method of choice at our
institution for myocardial protection. Continuous carbon dioxide insufflation
was used routinely after sternotomy until closure of the aortotomy. The
ascending aorta was incised transversally 1.5 cm above the sinotubular junction
in order to leave a free edge for closure of the aortotomy after implantation of
the device. The aortic valve was removed, and the annulus was decalcified in the
usual fashion. The aortic orifice was measured with the original sizer of the
bioprosthesis.</p><p>Three 4-0 polypropylene guiding sutures were passed at the nadir of the aortic
annulus. An appropriately sized prosthesis was collapsed in a side table and
placed into the manufacturer's holder.</p><p>The three guiding sutures were passed through the three green holes arising from
the annular ring of the prosthesis, which was consequently seated on the
debrided annulus. Once the delivery system is in position, the stent is deployed
by turning the release screw and leaving the valve in place. The delivery system
and the guiding sutures are removed. The field was rinsed with warm saline, and
the prosthesis was dilated at four atmospheres for 30 seconds. After closure of
the aortotomy, transesophageal echocardiography (TOE) was performed to assess
the correct implantation of the prosthesis and the presence of any PVL.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The mean age of the 139 patients was 74.3 years (range 47-86 years); 21.6% of
patients were &#x02265; 80 years old (<xref ref-type="table" rid="t1">Table
1</xref>). The procedure success rate was 97.1%. In four (2.8%) patients Perceval
valve was explanted mainly due to severe PVL, erroneous sizing or malpositioning
discovered during perioperative echocardiography. In each one of these cases, a
different prosthetic valve was eventually implanted. Mean crossclamping time and
bypass time were 40 and 63 minutes for isolated cases while 68 and 107 minutes for
combined cases.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Preoperative summary.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="55%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/><col width="15%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Total n = 139n</th><th align="center" colspan="2" rowspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gender (Male/Female)</td><td align="center" rowspan="1" colspan="1">65/74</td><td align="center" colspan="2" rowspan="1">47/53</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">Procedure types</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Isolated aortic valve
replacement (group A)</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" colspan="2" rowspan="1">66</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;AVR + CABG or other
procedures (group B)</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" colspan="2" rowspan="1">34</td></tr><tr><td align="left" rowspan="1" colspan="1">Cigarette smoking history</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" colspan="2" rowspan="1">60</td></tr><tr><td align="left" rowspan="1" colspan="1">History of hypertension</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" colspan="2" rowspan="1">76</td></tr><tr><td align="left" rowspan="1" colspan="1">Renal disease at time of surgery</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" colspan="2" rowspan="1">0.7</td></tr><tr><td align="left" rowspan="1" colspan="1">History of pulmonary disease (<italic>e.g.</italic>
COPD, asthma)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" colspan="2" rowspan="1">1.44</td></tr><tr><td align="left" rowspan="1" colspan="1">History of neurological disease (<italic>e.g</italic>.
TIA, CVA)</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" colspan="2" rowspan="1">18</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">Angina status pre-surgery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0. No angina</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" colspan="2" rowspan="1">35</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. No limitation of
physical activity</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" colspan="2" rowspan="1">24</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Slight limitation of
ordinary activity</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" colspan="2" rowspan="1">21</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Marked limitation of
ordinary physical activity</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" colspan="2" rowspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;4. Symptoms at rest or
minimal activity</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" colspan="2" rowspan="1">2</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">Dyspnoea status pre-surgery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. No limitation of
physical activity</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" colspan="2" rowspan="1">8.7</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Slight limitation of
ordinary physical activity</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" colspan="2" rowspan="1">38</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Marked limitation of
ordinary physical activity</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" colspan="2" rowspan="1">51</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;4. Symptoms at rest or
minimal activity</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" colspan="2" rowspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">History of Diabetes mellitus</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" colspan="2" rowspan="1">22</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">Preoperative heart rhythm</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;0. Sinus rhythm</td><td align="center" rowspan="1" colspan="1">109</td><td align="center" colspan="2" rowspan="1">78</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. Atrial
fibrillation/flutter</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" colspan="2" rowspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Complete heart
block/pacing</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" colspan="2" rowspan="1">1.4</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">Ejection fraction category</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td colspan="2" align="center" rowspan="1">&#x000a0;</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1. Good (LVEF &#x0003e;
50%)</td><td align="center" rowspan="1" colspan="1">111</td><td align="center" colspan="2" rowspan="1">80</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2. Fair (LVEF
30-50%)</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" colspan="2" rowspan="1">16</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3. Poor (LVEF &#x0003c;
30%)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" colspan="2" rowspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><bold>Range</bold></td><td align="center" rowspan="1" colspan="1"><bold>Mean</bold></td><td align="center" rowspan="1" colspan="1"><bold>Median</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">Age of patients at time of procedure</td><td align="center" rowspan="1" colspan="1">47-86</td><td align="center" rowspan="1" colspan="1">74.3</td><td align="center" rowspan="1" colspan="1">75.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Logistic EuroSCORE comparison&#x000a0;&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.53-18.886</td><td align="center" rowspan="1" colspan="1">3.26</td><td align="center" rowspan="1" colspan="1">2.457</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">140-185</td><td align="center" rowspan="1" colspan="1">162</td><td align="center" rowspan="1" colspan="1">162</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">40.3-158</td><td align="center" rowspan="1" colspan="1">79</td><td align="center" rowspan="1" colspan="1">74</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AVR=aortic valve replacement; CABG=coronary artery bypass grafting;
COPD=chronic obstructive pulmonary disease; CVA=cerebrovascular
accident; EuroSCORE=European System for Cardiac Operative Risk
Evaluation; LVEF=left ventricular ejection fraction; TIA=transient
ischemic attack</p></fn></table-wrap-foot></table-wrap><p>Size S (annulus range 19-21 mm) was implanted in 23 (17%) of patients, size M
(annulus range 21-23 mm) in 39 (28%), size L (annulus range 23-25 mm) in 42 (30%)
and size XL (annulus range 25-27 mm), which was available since July 2012, was
implanted in 35 (25%) of the eligible patients.</p><p>The mean length of intensive care unit (ICU) stay was 3.4 days (range 1-32 days,
median 1 day) in isolated AVR while it was 6.8 days (range 1-93 days, median 3 days)
in combined cases. Hospital stay was 11.7 days (median 8, range 4-48) for isolated
cases while it was 18.4 days (median 9, 4-225) for combined cases (<xref ref-type="table" rid="t2">Tables 2</xref> and <xref ref-type="table" rid="t3">3</xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Postoperative summary.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">&#x000a0;</th><th align="center" colspan="3" rowspan="1">Group A<break/>n = 92</th><th align="center" colspan="3" rowspan="1">Group B<break/>n = 47</th></tr><tr><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">Range</th><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Median</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cumulative cross-clamp time (min)</td><td align="center" rowspan="1" colspan="1">21-114</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">28-127</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">61</td></tr><tr><td align="left" rowspan="1" colspan="1">Cumulative bypass time</td><td align="center" rowspan="1" colspan="1">25-172</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">38-403</td><td align="center" rowspan="1" colspan="1">107</td><td align="center" rowspan="1" colspan="1">87</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative blood loss at 12 hours</td><td align="center" rowspan="1" colspan="1">50-2000</td><td align="center" rowspan="1" colspan="1">295</td><td align="center" rowspan="1" colspan="1">225</td><td align="center" rowspan="1" colspan="1">50-1200</td><td align="center" rowspan="1" colspan="1">457</td><td align="center" rowspan="1" colspan="1">400</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU stay in days</td><td align="center" rowspan="1" colspan="1">1&#x000a0;&#x000a0;&#x000a0;&#x000a0;32</td><td align="center" rowspan="1" colspan="1">3.4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1&#x000a0;&#x000a0;&#x000a0;&#x000a0;93</td><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1">3</td></tr><tr><td align="left" rowspan="1" colspan="1">Reoperation for bleeding, tamponade or valvular
problems</td><td align="center" rowspan="1" colspan="1">2 (1.4%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">1 (0.7%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>ICU=intensive care unit</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Postoperative summary.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">n = 139</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Reoperation for bleeding, tamponade or valvular
problems</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">Sternal wound infection</td><td align="center" rowspan="1" colspan="1">2/139</td><td align="center" rowspan="1" colspan="1">1.43%</td></tr><tr><td align="left" rowspan="1" colspan="1">New postoperative neurological dysfunction</td><td align="center" rowspan="1" colspan="1">4/139</td><td align="center" rowspan="1" colspan="1">2.8%</td></tr><tr><td align="left" rowspan="1" colspan="1">New HF/dialysis postoperatively</td><td align="center" rowspan="1" colspan="1">5/139</td><td align="center" rowspan="1" colspan="1">3.6%</td></tr><tr><td align="left" rowspan="1" colspan="1">Patient status at discharge (mortality)</td><td align="center" rowspan="1" colspan="1">3/139</td><td align="center" rowspan="1" colspan="1">2.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">SIRS</td><td align="center" rowspan="1" colspan="1">21/139</td><td align="center" rowspan="1" colspan="1">15%</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">Arrhythmias</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;None</td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">63%</td></tr><tr style="border-bottom:hidden"><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;AF/flutter</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">33%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Permanent
pacemaker</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">3.6%</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>AF=atrial fibrillation; HF=hemofiltration; SIRS=systemic inflammatory
response syndrome</p></fn></table-wrap-foot></table-wrap><p>No cases of unanticipated adverse device effects, valve thrombosis, secondary valve
dislodgement or valve-related haemolytic anaemia were reported. Five (3.6%) patients
developed renal failure and were connected to continuous venovenous hemofiltration
leading to recovery of renal function. Forty-six (33%) patients had postoperative
atrial fibrillation, were treated with betablockers or amiodarone and returned to
sinus rhythm. A total of 4 (2.8%) postoperative strokes occurred and 3 (2.1%) cases
of early bleeding led to reoperation. The incidence rate of permanent pacemaker
implantation was overall 3.6%.</p><p>The mean gradient across Perceval valve was found to be higher for the smaller and
lower for the larger valves. It ranges from 6-18 mmHg and its mean value was 12.5
mmHg. Similarly, its effective orifice area varies according to the valve sizes but
its mean value was 1.5 cm<sup>2</sup>.</p><p>In-hospital mortality was 2.1% (n=3). The first patient was a 70 years old man who
had AVR and CABG. He was re-intubated for respiratory compromise on day 3 and
aspirated during the procedure. He went into sepsis, renal failure and developed
ischemic colon. Finally, he died on day 13. The next one was a 70 years old male,
chronic smoker, severe chronic obstructive pulmonary disease, forced expiratory
volume in 1 second (FEV1) 1.4 lit (53% predicted). He underwent uneventful surgery
and ICU stay. On day 4, he had a run of ventricular tachycardia, followed by
respiratory and cardiac arrest. He was intubated, resuscitated and chest was opened.
There was no evidence of tamponade, at this stage he went into ventricular
fibrillation and finally died despite all resuscitation attempts. The last one was a
70 years old, 47 kg frail woman with severely impaired left ventricle and severe
aortic stenosis. She had uneventful surgery but died of low output syndrome and
heart failure on day 14.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Magovern &#x00026; Cromie<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> introduced the concept of sutureless aortic valve in the
1960s with the ball-cage-type mechanical valve for sutureless implantation. It had
its own disadvantages, <italic>e.g.</italic> high incidence of PVLs, bulky size and
not suitable for small annuli<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, high incidence of thromboembolism (42%) and reoperation
(16%)[6]. This valve continued to be used until 1980.</p><p>When aortic valve is replaced surgically, sutures are placed into the annulus and
then through the sewing cuff of the prosthetic valve. While at sutureless aortic
valve, it obviates the need to put sutures to fix the valve, and thus make the
procedure faster, cross-clamp and CPB times shorter, both are independent predictors
of 30 day postoperative mortality after adult cardiac surgery<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>High-risk patients, particularly those undergoing prolonged concomitant surgery and
redo surgery, could benefit from reduced length of time of the implantation by
avoiding the need to use sutures to secure the bioprosthesis within the aortic
annulus. Shrestha et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> also confirmed the safety and efficacy of the sutureless
aortic valve in patients requiring concomitant procedures. This is important as,
according to the Society of Thoracic Surgeons (STS) database, the proportion of
candidates requiring concomitant CABG has risen from 5 to 25% over the past 20
years.</p><p>The effective orifice area of the valve is more for any given valve size as there is
no ring for valve anchorage. This would be particularly beneficial for patients with
small aortic roots where risk of patient prosthesis mismatch is
high<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>Sutureless valves are also advantageous in minimally invasive AVR as it is
technically difficult to put annular sutures in such cases because of the limitation
of working space. Sutureless valves obviate this technical difficulty.</p><p>The durability of the Perceval valve is also an issue. Englberger et
al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>
presented the longest follow-up study for a sutureless bioprosthesis (5-year
follow-up) and suggested that sutureless valves become an option for all patients
with indicated biological AVR.</p><p>The PARTNER trial showed a significantly higher incidence of PVL following TAVI than
after surgical AVR at both 1 and 2 years<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. PVL has been identified as an independent
predictor of late mortality after TAVI<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. D'Onofrio et al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> showed that the incidence of PVL (at least
mild) was higher in a transapical TAVI group compared with a sutureless
bioprosthesis group (44.7% <italic>vs.</italic> 15.8%, respectively,
<italic>P</italic>=0.001). Unlike TAVI, it is technically possible to perform
repositioning and to exchange the sutureless valve intraoperatively if the result is
unsatisfactory.</p><p>PVL can be the result of inadequate sizing, malpositioning or inappropriate
decalcification of the annulus<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Recent evidence from TAVI trials has demonstrated a
significant correlation between PVL and poorer outcomes. PVL was demonstrated to be
a significant predictor of one-year mortality, even after multivariable
adjustment.</p><p>Unlike TAVI and similarly to conventional AVR, the sutureless AVR approach involves
excision of the calcified valve and prosthesis placement under direct visualization
on a still heart, which may reduce the risk of misplacement and
PVL<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.
Pollari et al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>
found shorter ICU stays, hospital stays, and intubation times in the sutureless
group then in the stented group.</p><p>Even in cases requiring explantation of Perceval, the procedure was easy and the
Perceval valve was removed without technical issues, as previously
described<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Careful patient selection and echocardiographic
assessment are crucial in choosing the proper size. Correct sizing of the valve is
critical to minimize PVL and this should be performed with TOE and intraoperative
sizing.</p><p>We have compared our perioperative and early postoperative results with other
published series using sutureless valves (<xref ref-type="table" rid="t4">Table
4</xref>). Most of the authors have used Perceval valve except two who used
Edwards Intuity and ATS 3f Enable valves. Our mean logistic EuroSCORE is less then
all of the studies as we have least comorbidities. Our cross-clamp and bypass time
for the isolated Perceval AVR is almost the same as for most of the studies but
longer then Folliguet et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, Flameng et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, Cavalier trial<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> and Pollari et
al.<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. We
replaced 2.8% valves for severe PVL. This rate was 1.9%, 2.1%, 1.2%, 1.6% and 0.8%
for Kocher et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, Martens et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, Santarpino et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, Shrestha et
al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> and
Cavalier trial<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>,
respectively. Folliguet et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> explanted 4.6% valves for severe PVL.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of our results with other published series using sutureless
valves.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Type of valve</th><th align="center" rowspan="1" colspan="1">Mean logistic EuroSCORE</th><th align="center" rowspan="1" colspan="1">Cross-clamp time min Isolated AVR</th><th align="center" rowspan="1" colspan="1">Bypass time min Isolated AVR</th><th align="center" rowspan="1" colspan="1">Severe PV leak/replacedvalve N (%)</th><th align="center" rowspan="1" colspan="1">AV block N (%)</th><th align="center" rowspan="1" colspan="1">Mortality</th><th align="center" rowspan="1" colspan="1">Meangradient mmHg</th><th align="center" rowspan="1" colspan="1">Mean effective orifice area cm<sup>2</sup></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Our study (2018) n=139</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">3.26 (0.53-18.8)</td><td align="center" rowspan="1" colspan="1">40 (21-114)</td><td align="center" rowspan="1" colspan="1">63 (25-172)</td><td align="center" rowspan="1" colspan="1">4 (2.8%)</td><td align="center" rowspan="1" colspan="1">5 (3.6%)</td><td align="center" rowspan="1" colspan="1">3 (2.1%)</td><td align="center" rowspan="1" colspan="1">12.5 (6-18)</td><td align="center" rowspan="1" colspan="1">1.5</td></tr><tr><td align="left" rowspan="1" colspan="1">D'Onofrio<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup> (2012) n=51</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">14.2&#x000b1;8.1</td><td align="center" rowspan="1" colspan="1">44&#x000b1;17</td><td align="center" rowspan="1" colspan="1">69&#x000b1;26</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">2 (5.3%)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">10.9&#x000b1;3.72</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Folliguet<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> (2012) n=208</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">8.7&#x000b1;5.3</td><td align="center" rowspan="1" colspan="1">30.1&#x000b1;12.2</td><td align="center" rowspan="1" colspan="1">50.3&#x000b1;22.8</td><td align="center" rowspan="1" colspan="1">9 (4.3%)</td><td align="center" rowspan="1" colspan="1">16 (7.7%)</td><td align="center" rowspan="1" colspan="1">5 (2.4%)</td><td align="center" rowspan="1" colspan="1">10.4&#x000b1;4.3</td><td align="center" rowspan="1" colspan="1">1.4&#x000b1;0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Kocher<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> (2013) n=146</td><td align="center" rowspan="1" colspan="1">Edwards Intuity</td><td align="center" rowspan="1" colspan="1">7.9&#x000b1;6.5</td><td align="center" rowspan="1" colspan="1">41.1&#x000b1;10.6</td><td align="center" rowspan="1" colspan="1">66.3&#x000b1;18.7</td><td align="center" rowspan="1" colspan="1">2 (1.9%) but after 30 days</td><td align="center" rowspan="1" colspan="1">10 (7.1%)</td><td align="center" rowspan="1" colspan="1">3 (2.1)</td><td align="center" rowspan="1" colspan="1">8.8&#x000b1;3.0</td><td align="center" rowspan="1" colspan="1">1.7&#x000b1;0.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Martens<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> (2011) n=140</td><td align="center" rowspan="1" colspan="1">ATS 3f Enable</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">58.1&#x000b1;25.1Including combined procedures</td><td align="center" rowspan="1" colspan="1">84.9&#x000b1;34.2Including combined procedures</td><td align="center" rowspan="1" colspan="1">3 (2.1%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">5 (3.6%)</td><td align="center" rowspan="1" colspan="1">10.24&#x000b1;4.2</td><td align="center" rowspan="1" colspan="1">1.75&#x000b1;0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">Santarpino<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> (2012) n=83</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">10&#x000b1;7.5</td><td align="center" rowspan="1" colspan="1">36&#x000b1;12.7</td><td align="center" rowspan="1" colspan="1">66&#x000b1;21</td><td align="center" rowspan="1" colspan="1">1 (1.2%)</td><td align="center" rowspan="1" colspan="1">3 (3.6%)</td><td align="center" rowspan="1" colspan="1">2 (2.4%)</td><td align="center" rowspan="1" colspan="1">13.4&#x000b1;2.8</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Flameng<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> (2011) n=32</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">9.99</td><td align="center" rowspan="1" colspan="1">17 (12-34)</td><td align="center" rowspan="1" colspan="1">46(24-120)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">1 (3.1%) 6-12 months after surgery</td><td align="center" rowspan="1" colspan="1">3 (9.4%) 6-12 months after surgery</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">1.5 (0.8-2.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Shrestha<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup> (2014) n=243</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">12.1</td><td align="center" rowspan="1" colspan="1">50.7&#x000b1;22.8 including combined procedures</td><td align="center" rowspan="1" colspan="1">78.9&#x000b1;32.3 including combined procedures</td><td align="center" rowspan="1" colspan="1">4 (1.6%)</td><td align="center" rowspan="1" colspan="1">14 (5.9%)</td><td align="center" rowspan="1" colspan="1">5(2.1%)</td><td align="center" rowspan="1" colspan="1">10.1 &#x000b1; 4.7</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1; 0.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Cavalier trial<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> (2016) n = 658</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">10.2&#x000b1;7.8</td><td align="center" rowspan="1" colspan="1">35.3&#x000b1;12.1</td><td align="center" rowspan="1" colspan="1">58.4&#x000b1;20.2</td><td align="center" rowspan="1" colspan="1">5 (0.8)</td><td align="center" rowspan="1" colspan="1">42 (6.7%)</td><td align="center" rowspan="1" colspan="1">23 (3.7)</td><td align="center" rowspan="1" colspan="1">10.24</td><td align="center" rowspan="1" colspan="1">1.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Gilmanov<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> (2014) n=133</td><td align="center" rowspan="1" colspan="1">Predominantly Perceval S</td><td align="center" rowspan="1" colspan="1">7.5&#x000a0; (4.8-11)</td><td align="center" rowspan="1" colspan="1">56 (48-72.5)</td><td align="center" rowspan="1" colspan="1">90 (78-108.5)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">3 (2.3%)</td><td align="center" rowspan="1" colspan="1">2 (1.5)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Pollari<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> (2014) n=133</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">14&#x000b1;7.4</td><td align="center" rowspan="1" colspan="1">35&#x000b1;12</td><td align="center" rowspan="1" colspan="1">71&#x000b1;11</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">5 (6.1%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Dal&#x000e9;n<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> (2016) n=182</td><td align="center" rowspan="1" colspan="1">Perceval S</td><td align="center" rowspan="1" colspan="1">10.6&#x000b1;7.5</td><td align="center" rowspan="1" colspan="1">41&#x000b1;17</td><td align="center" rowspan="1" colspan="1">69&#x000b1;23</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">3 (1.6)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>AV = atrioventricular; AVR=aortic valve replacement; EuroSCORE=European
System for Cardiac Operative Risk Evaluation; PV = paravalvular.</p></fn></table-wrap-foot></table-wrap><p>Complete heart block requiring permanent pacemaker is a known complication of AVR.
This incidence was 3.6% in our study which matches quite well with Santarpino et
al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> and
Flameng et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>
but slightly more than Gilmanov et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> (2.3%). Permanent pacemaker requirement in our
study was much less than all the other mentioned studies. Early 30-day mortality was
2.1% in our study, which is almost the same as all the other compared studies. In
Flameng et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>
study, 3 (9.4%) patients died after 6-12 months of surgery. We have shown
pre-discharge mean gradient across aortic valve of 12.5 mmHg and its effective
orifice area of 1.5 cm<sup>2</sup>. These values correlate well with all the
compared studies.</p><sec><title>Limitations</title><p>The major limitation of this study is that it was based on data from a single
institution and limited number of cases. Moreover, there is the lack of a
control group and a randomization in its design. This study showed only early
outcomes, and it remains necessary to obtain data documenting long-term
performance.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Perceval valve in aortic position is safe and feasible. Sutureless AVR may become the
first choice of procedure in the elderly high-risk population. Further follow-up is
needed to evaluate the long-term outcome with this bioprosthesis.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SSM</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SL</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ARS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SC</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TP</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Department of Cardiothoracic Surgery, Freeman
Hospital, Freeman Road, United Kingdom of Great Britain and Northern
Ireland.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bridgewater</surname><given-names>B</given-names></name><name><surname>Gummert</surname><given-names>J</given-names></name><name><surname>Kinsman</surname><given-names>R</given-names></name><name><surname>Walton</surname><given-names>PKH</given-names></name></person-group><article-title>Towards global benchmarking: the Fourth EACTS Adult Cardiac
Surgical Database Report</article-title><source>Interact CardioVasc Thorac Surg</source><year>2011</year><volume>12</volume><issue>1</issue><fpage>4</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">21177301</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>RA</given-names></name><name><surname>Otto</surname><given-names>CM</given-names></name><name><surname>Bonow</surname><given-names>RO</given-names></name><name><surname>Carabello</surname><given-names>BA</given-names></name><name><surname>3rd</surname><given-names>Erwin GP</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><etal/><collab>ACC/AHA Task Force Members</collab></person-group><article-title>2014 AHA/ACC Guideline for the management of patients with
valvular heart disease: executive summary: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines</article-title><source>Circulation</source><year>2014</year><volume>129</volume><issue>23</issue><fpage>2440</fpage><lpage>2492</lpage><pub-id pub-id-type="pmid">24589852</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zahn</surname><given-names>R</given-names></name><name><surname>Gerckens</surname><given-names>U</given-names></name><name><surname>Grube</surname><given-names>E</given-names></name><name><surname>Linke</surname><given-names>A</given-names></name><name><surname>Sievert</surname><given-names>H</given-names></name><name><surname>Eggebrecht</surname><given-names>H</given-names></name><etal/><collab>German Transcatheter Aortic Valve Interventions-Registry
Investigators</collab></person-group><article-title>Transcatheter aortic valve implantation: first results from a
multi-centre real-world registry</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><issue>2</issue><fpage>198</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">20864486</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eichstaedt</surname><given-names>HC</given-names></name><name><surname>Easo</surname><given-names>J</given-names></name><name><surname>Harle</surname><given-names>T</given-names></name><name><surname>Dapunt</surname><given-names>OE</given-names></name></person-group><article-title>Early single-center experience in sutureless aortic valve
implantation in 120 patients</article-title><source>J Thorac Cardiovasc Surg</source><year>2014</year><volume>147</volume><issue>1</issue><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="pmid">23473011</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magovern</surname><given-names>GJ</given-names></name><name><surname>Cromie</surname><given-names>HW</given-names></name></person-group><article-title>Sutureless prosthetic heart valves</article-title><source>J Thorac Cardiovasc Surg</source><year>1963</year><volume>46</volume><fpage>726</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">14099081</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>SM</given-names></name><name><surname>Sethi</surname><given-names>GK</given-names></name><name><surname>Flye</surname><given-names>MW</given-names></name><name><surname>Takaro</surname><given-names>T</given-names></name></person-group><article-title>The sutureless aortic valve prosthesis: experience with and
technical considerations for replacement of the early model</article-title><source>Ann Surg</source><year>1976</year><volume>184</volume><issue>2</issue><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">133642</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nissinen</surname><given-names>J</given-names></name><name><surname>Biancari</surname><given-names>F</given-names></name><name><surname>Wistbacka</surname><given-names>JO</given-names></name><name><surname>Peltola</surname><given-names>T</given-names></name><name><surname>Loponen</surname><given-names>P</given-names></name><name><surname>Tarkiainen</surname><given-names>P</given-names></name><etal/></person-group><article-title>Safe time limits of aortic cross-clamping and cardiopulmonary
bypass in adult cardiac surgery</article-title><source>Perfusion</source><year>2009</year><volume>24</volume><issue>5</issue><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">20007817</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>M</given-names></name><name><surname>Folliguet</surname><given-names>TA</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name><name><surname>Meuris</surname><given-names>B</given-names></name><name><surname>Carrel</surname><given-names>T</given-names></name><name><surname>Bechtel</surname><given-names>M</given-names></name><etal/></person-group><article-title>Aortic valve replacement and concomitant procedures with the
Perceval valve: results of European Trials</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>98</volume><issue>4</issue><fpage>1294</fpage><lpage>1300</lpage><pub-id pub-id-type="pmid">25106682</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shrestha</surname><given-names>M</given-names></name><name><surname>Maeding</surname><given-names>I</given-names></name><name><surname>H&#x000f6;ffler</surname><given-names>K</given-names></name><name><surname>Koigeldiyev</surname><given-names>N</given-names></name><name><surname>Marsch</surname><given-names>G</given-names></name><name><surname>Siemeni</surname><given-names>T</given-names></name><etal/></person-group><article-title>Aortic valve replacement in geriatric patients with small aortic
roots: are sutureless valves the future?</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2013</year><volume>17</volume><issue>5</issue><fpage>778</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">23851988</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Englberger</surname><given-names>L</given-names></name><name><surname>Carrel</surname><given-names>TP</given-names></name><name><surname>Doss</surname><given-names>M</given-names></name><name><surname>Sadowski</surname><given-names>J</given-names></name><name><surname>Bartus</surname><given-names>K</given-names></name><name><surname>Eckstein</surname><given-names>FF</given-names></name><etal/></person-group><article-title>Clinical performance of a sutureless aortic bioprosthesis:
five-year results of the 3f Enable long-term follow-up study</article-title><source>J Thorac Cardiovasc Surg</source><year>2014</year><volume>148</volume><issue>4</issue><fpage>1681</fpage><lpage>1687</lpage><pub-id pub-id-type="pmid">24787699</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kodali</surname><given-names>SK</given-names></name><name><surname>Williams</surname><given-names>MR</given-names></name><name><surname>Smith</surname><given-names>CR</given-names></name><name><surname>Svensson</surname><given-names>LG</given-names></name><name><surname>Webb</surname><given-names>JG</given-names></name><name><surname>Makkar</surname><given-names>RR</given-names></name><etal/><collab>PARTNER Trial Investigators</collab></person-group><article-title>Two-year outcomes after transcatheter or surgical aortic-valve
replacement</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>18</issue><fpage>1686</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">22443479</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamburino</surname><given-names>C</given-names></name><name><surname>Capodanno</surname><given-names>D</given-names></name><name><surname>Ramondo</surname><given-names>A</given-names></name><name><surname>Petronio</surname><given-names>AS</given-names></name><name><surname>Ettori</surname><given-names>F</given-names></name><name><surname>Santoro</surname><given-names>G</given-names></name><etal/></person-group><article-title>Incidence and predictors of early and late mortality after
transcatheter aortic valve implantation in 663 patients with severe aortic
stenosis</article-title><source>Circulation</source><year>2011</year><volume>123</volume><issue>3</issue><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">21220731</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Onofrio</surname><given-names>A</given-names></name><name><surname>Messina</surname><given-names>A</given-names></name><name><surname>Lorusso</surname><given-names>R</given-names></name><name><surname>Alfieri</surname><given-names>OR</given-names></name><name><surname>Fusari</surname><given-names>M</given-names></name><name><surname>Rubino</surname><given-names>P</given-names></name><etal/></person-group><article-title>Sutureless aortic valve replacement as an alternative treatment
for patients belonging to the "gray zone" between transcatheter aortic valve
implantation and conventional surgery: a propensity-matched, multicenter
analysis</article-title><source>J Thorac Cardiovasc Surg</source><year>2012</year><volume>144</volume><issue>5</issue><fpage>1010</fpage><lpage>1016</lpage><pub-id pub-id-type="pmid">22974713</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Folliguet</surname><given-names>TA</given-names></name><name><surname>Laborde</surname><given-names>F</given-names></name><name><surname>Zannis</surname><given-names>K</given-names></name><name><surname>Ghorayeb</surname><given-names>G</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><name><surname>Shrestha</surname><given-names>M</given-names></name></person-group><article-title>Sutureless Perceval aortic valve replacement: results of two
European centers</article-title><source>Ann Thorac Surg</source><year>2012</year><volume>93</volume><issue>5</issue><fpage>1483</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">22541180</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Eusanio</surname><given-names>M</given-names></name><name><surname>Phan</surname><given-names>K</given-names></name></person-group><article-title>Sutureless aortic valve replacement</article-title><source>Ann Cardiothor Surg</source><year>2015</year><volume>4</volume><issue>2</issue><fpage>123</fpage><lpage>130</lpage></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pollari</surname><given-names>F</given-names></name><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Dell'Aquila</surname><given-names>AM</given-names></name><name><surname>Gazdag</surname><given-names>L</given-names></name><name><surname>Alnahas</surname><given-names>H</given-names></name><name><surname>Vogt</surname><given-names>F</given-names></name></person-group><article-title>Better short-term outcome by using sutureless valves: a
propensity-matched score analysis</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>98</volume><issue>2</issue><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">24928678</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name><name><surname>Concistr&#x000e8;</surname><given-names>G</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name></person-group><article-title>A supra-annular malposition of the Perceval S sutureless aortic
valve: the '&#x003c7;-movement' removal technique and subsequent
reimplantation</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2012</year><issue>15</issue><fpage>280</fpage><lpage>281</lpage><pub-id pub-id-type="pmid">22535542</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flameng</surname><given-names>W</given-names></name><name><surname>Herregods</surname><given-names>MC</given-names></name><name><surname>Hermans</surname><given-names>H</given-names></name><name><surname>Van der Mieren</surname><given-names>G</given-names></name><name><surname>Vercalsteren</surname><given-names>M</given-names></name><name><surname>Poortmans</surname><given-names>G</given-names></name><etal/></person-group><article-title>Effect of sutureless implantation of the Perceval S aortic valve
bioprosthesis on intraoperative and early postoperative
outcomes</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>142</volume><issue>6</issue><fpage>1453</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">21474151</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laborde</surname><given-names>F</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name><name><surname>Hakim-Meibodi</surname><given-names>K</given-names></name><name><surname>Misfeld</surname><given-names>M</given-names></name><name><surname>Carrel</surname><given-names>T</given-names></name><name><surname>Zembala</surname><given-names>M</given-names></name><etal/><collab>Cavalier Trial Investigators</collab></person-group><article-title>Clinical and haemodynamic outcomes in 658 patients receiving the
Perceval sutureless aortic valve: early results from a prospective European
multicentre study (the Cavalier Trial)</article-title><source>Eur J Cardiothorac Surg</source><year>2016</year><volume>49</volume><issue>3</issue><fpage>978</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">26245628</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kocher</surname><given-names>AA</given-names></name><name><surname>Laufer</surname><given-names>G</given-names></name><name><surname>Haverich</surname><given-names>A</given-names></name><name><surname>Shrestha</surname><given-names>M</given-names></name><name><surname>Walther</surname><given-names>T</given-names></name><name><surname>Misfeld</surname><given-names>M</given-names></name><etal/></person-group><article-title>One-year outcomes of the Surgical Treatment of Aortic Stenosis
with a Next Generation Surgical Aortic Valve (TRITON) trial: a prospective
multicenter study of rapid-deployment aortic valve replacement with the
EDWARDS INTUITY Valve System</article-title><source>J Thorac Cardiovasc Surg</source><year>2013</year><volume>145</volume><issue>1</issue><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">23058665</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens</surname><given-names>S</given-names></name><name><surname>Sadowski</surname><given-names>J</given-names></name><name><surname>Eckstein</surname><given-names>FS</given-names></name><name><surname>Bartus</surname><given-names>K</given-names></name><name><surname>Kapelak</surname><given-names>B</given-names></name><name><surname>Sievers</surname><given-names>HH</given-names></name><etal/></person-group><article-title>Clinical experience with the ATS 3f Enable(r) Sutureless
Bioprosthesis</article-title><source>Eur J Cardiothorac Surg</source><year>2011</year><volume>40</volume><issue>3</issue><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">21342776</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Pfeiffer</surname><given-names>S</given-names></name><name><surname>Schmidt</surname><given-names>J</given-names></name><name><surname>Concistr&#x000e8;</surname><given-names>G</given-names></name><name><surname>Fischlein</surname><given-names>T</given-names></name></person-group><article-title>Sutureless aortic valve replacement: first-year single-center
experience</article-title><source>Ann Thorac Surg</source><year>2012</year><volume>94</volume><issue>2</issue><fpage>504</fpage><lpage>508</lpage><pub-id pub-id-type="pmid">22695049</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilmanov</surname><given-names>D</given-names></name><name><surname>Miceli</surname><given-names>A</given-names></name><name><surname>Ferrarini</surname><given-names>M</given-names></name><name><surname>Farneti</surname><given-names>P</given-names></name><name><surname>Murzi</surname><given-names>M</given-names></name><name><surname>Solinas</surname><given-names>M</given-names></name><etal/></person-group><article-title>Aortic valve replacement through right anterior minithoracotomy:
can sutureless technology improve clinical outcomes?</article-title><source>Ann Thorac Surg</source><year>2014</year><volume>98</volume><issue>5</issue><fpage>1585</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">25200732</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dal&#x000e9;n</surname><given-names>M</given-names></name><name><surname>Biancari</surname><given-names>F</given-names></name><name><surname>Rubino</surname><given-names>AS</given-names></name><name><surname>Santarpino</surname><given-names>G</given-names></name><name><surname>Glaser</surname><given-names>N</given-names></name><name><surname>De Praetere</surname><given-names>H</given-names></name><etal/></person-group><article-title>Aortic valve replacement through full sternotomy with a stented
bioprosthesis versus minimally invasive sternotomy with a sutureless
bioprosthesis</article-title><source>Eur J Cardiothorac Surg</source><year>2016</year><volume>49</volume><issue>1</issue><fpage>220</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">25653252</pub-id></element-citation></ref></ref-list></back></article>